Cargando…
Clinical advances and ongoing trials of mRNA vaccines for cancer treatment
Years of research exploring mRNA vaccines for cancer treatment in preclinical and clinical trials have set the stage for the rapid development of mRNA vaccines during the COVID-19 pandemic. Therapeutic cancer vaccines based on mRNA are well tolerated, and the inherent advantage in ease of production...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512276/ https://www.ncbi.nlm.nih.gov/pubmed/36174631 http://dx.doi.org/10.1016/S1470-2045(22)00372-2 |
_version_ | 1784797815869800448 |
---|---|
author | Lorentzen, Cathrine Lund Haanen, John B Met, Özcan Svane, Inge Marie |
author_facet | Lorentzen, Cathrine Lund Haanen, John B Met, Özcan Svane, Inge Marie |
author_sort | Lorentzen, Cathrine Lund |
collection | PubMed |
description | Years of research exploring mRNA vaccines for cancer treatment in preclinical and clinical trials have set the stage for the rapid development of mRNA vaccines during the COVID-19 pandemic. Therapeutic cancer vaccines based on mRNA are well tolerated, and the inherent advantage in ease of production, which rivals the best available conventional vaccine manufacture methods, renders mRNA vaccines a promising option for cancer immunotherapy. Technological advances have optimised mRNA-based vaccine stability, structure, and delivery methods, and multiple clinical trials investigating mRNA vaccine therapy are now enrolling patients with various cancer diagnoses. Although therapeutic mRNA-based cancer vaccines have not yet been approved for standard treatment, encouraging results from early clinical trials with mRNA vaccines as monotherapy and in combination with checkpoint inhibitors have been obtained. This Review summarises the latest clinical advances in mRNA-based vaccines for cancer treatment and reflects on future perspectives and challenges for this new and promising treatment approach. |
format | Online Article Text |
id | pubmed-9512276 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95122762022-09-27 Clinical advances and ongoing trials of mRNA vaccines for cancer treatment Lorentzen, Cathrine Lund Haanen, John B Met, Özcan Svane, Inge Marie Lancet Oncol Review Years of research exploring mRNA vaccines for cancer treatment in preclinical and clinical trials have set the stage for the rapid development of mRNA vaccines during the COVID-19 pandemic. Therapeutic cancer vaccines based on mRNA are well tolerated, and the inherent advantage in ease of production, which rivals the best available conventional vaccine manufacture methods, renders mRNA vaccines a promising option for cancer immunotherapy. Technological advances have optimised mRNA-based vaccine stability, structure, and delivery methods, and multiple clinical trials investigating mRNA vaccine therapy are now enrolling patients with various cancer diagnoses. Although therapeutic mRNA-based cancer vaccines have not yet been approved for standard treatment, encouraging results from early clinical trials with mRNA vaccines as monotherapy and in combination with checkpoint inhibitors have been obtained. This Review summarises the latest clinical advances in mRNA-based vaccines for cancer treatment and reflects on future perspectives and challenges for this new and promising treatment approach. Elsevier Ltd. 2022-10 2022-09-26 /pmc/articles/PMC9512276/ /pubmed/36174631 http://dx.doi.org/10.1016/S1470-2045(22)00372-2 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Lorentzen, Cathrine Lund Haanen, John B Met, Özcan Svane, Inge Marie Clinical advances and ongoing trials of mRNA vaccines for cancer treatment |
title | Clinical advances and ongoing trials of mRNA vaccines for cancer treatment |
title_full | Clinical advances and ongoing trials of mRNA vaccines for cancer treatment |
title_fullStr | Clinical advances and ongoing trials of mRNA vaccines for cancer treatment |
title_full_unstemmed | Clinical advances and ongoing trials of mRNA vaccines for cancer treatment |
title_short | Clinical advances and ongoing trials of mRNA vaccines for cancer treatment |
title_sort | clinical advances and ongoing trials of mrna vaccines for cancer treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512276/ https://www.ncbi.nlm.nih.gov/pubmed/36174631 http://dx.doi.org/10.1016/S1470-2045(22)00372-2 |
work_keys_str_mv | AT lorentzencathrinelund clinicaladvancesandongoingtrialsofmrnavaccinesforcancertreatment AT haanenjohnb clinicaladvancesandongoingtrialsofmrnavaccinesforcancertreatment AT metozcan clinicaladvancesandongoingtrialsofmrnavaccinesforcancertreatment AT svaneingemarie clinicaladvancesandongoingtrialsofmrnavaccinesforcancertreatment |